Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings

(2013) T. M. A. Abdel-Fatah et al.   ANNALS OF ONCOLOGY

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Breast cancer: Current and future endocrine therapies

(2013) Carlo Palmieri et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

The Genomic Landscape of Breast Cancer as a Therapeutic Roadmap

(2013) Matthew J. Ellis et al.   Cancer Discovery

Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy

(2012) R. Sultana et al.   CANCER RESEARCH

ATF2 – at the crossroad of nuclear and cytosolic functions

(2012) Eric Lau et al.   JOURNAL OF CELL SCIENCE

Phosphorylation of ATF2 and interaction with NFY induces c-Jun in the gonadotrope

(2012) Lacey L. Lindaman et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Regulation of Aldosterone Synthase by Activator Transcription Factor/cAMP Response Element-Binding Protein Family Members

(2010) Edson F. Nogueira et al.   ENDOCRINOLOGY

Nucleosome dynamics define transcriptional enhancers

(2010) Housheng Hansen He et al.   NATURE GENETICS

Activating Transcription Factor 2 and c-Jun-Mediated Induction of FoxP3 for Experimental Therapy of Mammary Tumor in the Mouse

(2009) Y. Liu et al.   CANCER RESEARCH

Phosphorylation of Activation Transcription Factor-2 at Serine 121 by Protein Kinase C Controls c-Jun-mediated Activation of Transcription

(2009) Takahito Yamasaki et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Suppressor role of activating transcription factor 2 (ATF2) in skin cancer

(2008) A. Bhoumik et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA